BeOne Medicines (ONC) Aktievy
BeOne Medicines AG, ett onkologibolag, är verksamt inom upptäckt och utveckling av olika behandlingar för cancerpatienter i USA, Kina, Europa och internationellt. Mer information
| Snöflinga Score | |
|---|---|
| Värdering | 2/6 |
| Framtida tillväxt | 4/6 |
| Tidigare resultat | 3/6 |
| Finansiell hälsa | 5/6 |
| Utdelningar | 0/6 |
ONC Community Fair Values
Create NarrativeSee what 37 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
BeOne Medicines AG Konkurrenter
Prishistorik och prestanda
| Historiska aktiekurser | |
|---|---|
| Aktuell aktiekurs | US$374.47 |
| 52 veckors högsta | US$385.22 |
| 52 veckors lägsta | US$253.95 |
| Beta | 0.50 |
| 1 månads förändring | 14.90% |
| 3 månaders förändring | 23.82% |
| 1 års förändring | 21.33% |
| 3 års förändring | 85.30% |
| 5 års förändring | 24.07% |
| Förändring sedan börsintroduktionen | 1,222.28% |
Senaste nyheter och uppdateringar
Uppdatering av berättelse • Aug 20
ONC: Hematology Pipeline And Solid Tumor Catalysts Will Drive Future Upside
BeOne Medicines' analyst fair value estimate has shifted to $433.02 from $412.35, as analysts factor in higher price targets following recent beat and raise quarters, supported by progress across both solid tumor and hematology pipelines. Analyst Commentary Recent Street research on BeOne Medicines points to a generally constructive tone, with most firms adjusting price targets higher after the latest beat and raise quarter and pipeline updates.Analysartikel • Aug 12
Solid Earnings Reflect BeOne Medicines' (NASDAQ:ONC) Strength As A Business
When companies post strong earnings, the stock generally performs well, just like BeOne Medicines AG's ( NASDAQ:ONC...Recent updates
Uppdatering av berättelse • Aug 20
ONC: Hematology Pipeline And Solid Tumor Catalysts Will Drive Future Upside
BeOne Medicines' analyst fair value estimate has shifted to $433.02 from $412.35, as analysts factor in higher price targets following recent beat and raise quarters, supported by progress across both solid tumor and hematology pipelines. Analyst Commentary Recent Street research on BeOne Medicines points to a generally constructive tone, with most firms adjusting price targets higher after the latest beat and raise quarter and pipeline updates.Analysartikel • Aug 12
Solid Earnings Reflect BeOne Medicines' (NASDAQ:ONC) Strength As A Business
When companies post strong earnings, the stock generally performs well, just like BeOne Medicines AG's ( NASDAQ:ONC...
Uppdatering av berättelse • Aug 06
ONC: Hematology Execution And 2026 Readouts Will Support Re Rating
BeOne Medicines' updated analyst price target edges higher as analysts factor in a fair value estimate moving to about $495, a slightly higher discount rate, more moderate revenue growth, improved profit margin expectations, and a lower assumed future P/E multiple following recent research updates from major firms. Analyst Commentary Recent research updates paint a constructive picture for BeOne Medicines, with several bullish analysts highlighting a mix of product execution, pipeline progress, and sector positioning as key supports for the stock's current valuation framework.Seeking Alpha • Jul 30
BeOne Medicines: Owning The Full B-Cell Treatment Sequence
Summary BeOne Medicines is transitioning from a BRUKINSA-driven story to an integrated hematology and oncology platform with multiple growth drivers. Q1 2026 results show 35.5% revenue growth, expanding margins, and rising profitability, supporting a premium valuation justified by strong operational leverage. BRUKINSA, BEQALZI, and tacabrutideg form a defensible three-asset hematology moat, while a solid-tumor pipeline and manufacturing expansion drive future diversification. Despite high concentration risk and a demanding valuation, ONC’s evolving product ecosystem and cash flow generation underpin a bullish outlook. Read the full article on Seeking Alpha
Uppdatering av berättelse • Jul 13
ONC: Hematology Leadership And Solid Tumor Data Will Drive Future Upside
Analysts have nudged their fair value estimate for BeOne Medicines higher from $336.98 to $344.15, reflecting updated assumptions around revenue growth, profit margins, and Brukinsa and pipeline momentum cited in recent price target increases across the Street. Analyst Commentary Recent Street research on BeOne Medicines points to a generally constructive stance, with several firms lifting price targets in conjunction with sector-wide optimism around biotech earnings and deal activity.Uppdatering av berättelse • Jun 24
ONC: Hematology Data And Solid Tumor Readouts Will Drive Future Upside
Analysts have nudged their average price targets higher for BeOne Medicines, pointing to recent FDA progress on sonrotoclax and encouraging ASCO solid tumor data as key reasons for modestly higher fair value estimates and slightly adjusted assumptions on growth, margins and future P/E. Analyst Commentary Recent Street research on BeOne Medicines points to a generally constructive tone, with several bullish analysts adjusting their models after new clinical data and the FDA decision on sonrotoclax.Uppdatering av berättelse • Jun 06
ONC: Hematology Leadership And Solid Tumor Pipeline Will Drive Future Upside
Analysts have nudged the fair value estimate for BeOne Medicines to about $337 per share, citing higher price targets from several firms as they factor in the recent accelerated approval of sonrotoclax and updated views on the company’s solid tumor pipeline. Analyst Commentary Recent research on BeOne Medicines reflects a mixed set of views.Uppdatering av berättelse • May 23
ONC: Hematology Franchise And Upcoming Trial Readouts Will Support Future Upside
Analysts lifted the price target on BeOne Medicines by $3 to $411.51, as updated models reflect the recent FDA accelerated approval for sonrotoclax in relapse and refractory mantle cell lymphoma, along with ongoing combination trials and a higher assumed profit margin that more than offsets slightly lower projected revenue growth and a reduced future P/E multiple. Analyst Commentary Recent research on BeOne Medicines centers on how the first FDA accelerated approval for sonrotoclax and the outlook for Brukinsa affect valuation, growth expectations, and perceived execution risk.Analysartikel • May 08
Results: BeOne Medicines AG Beat Earnings Expectations And Analysts Now Have New Forecasts
As you might know, BeOne Medicines AG ( NASDAQ:ONC ) just kicked off its latest quarterly results with some very strong...Uppdatering av berättelse • Apr 30
ONC: Hematology Leadership And 2026 Pipeline Readouts Will Re Rate Shares
BeOne Medicines' updated analyst price target reflects a modest adjustment, with fair value moving by about $1 per share as analysts balance slightly higher revenue and profit margin assumptions with a lower future P/E multiple following recent target changes and mixed rating updates across the Street. Analyst Commentary Recent research updates on BeOne Medicines show a mix of views, but there is a clear cluster of bullish analysts who see support for the current valuation and room for further upside based on execution around core products and the pipeline.Uppdatering av berättelse • Apr 16
ONC: Hematology Strength And Slower Pipeline Progress Will Shape Fairly Valued Shares
The updated analyst price target for BeOne Medicines shifts to $336 from $321, as analysts factor in slightly higher modeled revenue growth, profit margins, and future P/E assumptions, alongside mixed recent research that includes both trims and increases in published targets. Analyst Commentary Recent research around BeOne Medicines reflects a mix of enthusiasm for its core hematology asset and a more cautious reset on what investors should pay for that story.Uppdatering av berättelse • Apr 02
ONC: Hematology Pipeline Strength And Upcoming Data Readouts Will Drive Future Upside
BeOne Medicines' analyst price target has been nudged higher to reflect a fair value estimate of about $408, as analysts balance slightly softer long term growth and margin assumptions with ongoing confidence in Brukinsa and the broader hematology pipeline, including support from several recent target hikes and one downgrade to Hold. Analyst Commentary Bullish Takeaways Bullish analysts highlight Brukinsa as a core value driver, treating it as one of the stronger hematology assets and a key pillar supporting current fair value estimates in the low $400s.Uppdatering av berättelse • Mar 19
ONC: Hematology Franchise Strength And Pipeline Readouts Will Re Rate Shares
BeOne Medicines' updated analyst price target has moved lower, reflecting a reduced fair value estimate to $478.80 as analysts factor in more moderate revenue growth, slimmer profit margins, a slightly higher discount rate, and a higher future P/E multiple. This multiple is anchored by strong Brukinsa performance but a slower build for the next wave of assets.Uppdatering av berättelse • Mar 04
ONC: Brukinsa Reliance And Hematology Pipeline Will Shape Fairly Valued Shares
The analyst price target for BeOne Medicines has been nudged higher by about $13 to align with a fair value update to roughly $321. Analysts are factoring in Q4 results, ongoing Brukinsa performance, and a higher future P/E assumption, alongside slightly more conservative revenue growth and profit margin inputs.Uppdatering av berättelse • Feb 18
ONC: Hematology Pipeline Hype Will Pressure Shares If Execution Slips
Analysts have raised their price targets on BeOne Medicines by $9, citing a pipeline they view as underappreciated by the market and supporting that view with updated assumptions regarding growth, profitability, and valuation multiples. Analyst Commentary Recent research has centered on how fully the market is pricing BeOne Medicines' drug pipeline and long term earnings power into the current share price.Uppdatering av berättelse • Feb 04
ONC: Hematology And Solid Tumor Pipeline Progress Will Drive Future Upside
Analysts lifted their price target for BeOne Medicines to about $404, up roughly $3, citing increased conviction in the value of its hematology and solid tumor pipeline, which is reflected in a slightly higher assumed future P/E multiple. Analyst Commentary Recent research updates on BeOne Medicines cluster around a similar theme: bullish analysts are raising price targets and citing comfort with both the hematology and solid tumor franchises, while also highlighting execution risks that investors should keep in mind.Uppdatering av berättelse • Jan 21
ONC: Hematology Franchise And Oncology Pipeline Are Expected To Re Rate Shares
Analysts have lifted their price targets on BeOne Medicines into the low US$400s, and our fair value estimate has edged up to about US$508 as they highlight what they see as underappreciation of the pipeline, the potential for best in class hematology assets, and additional upside from oncology trial updates. Analyst Commentary Recent Street research on BeOne Medicines has tilted clearly positive, with a series of price target increases into the low US$400s range and at least one rating upgrade.Uppdatering av berättelse • Jan 07
ONC: Fair View Balances Blood Cancer Progress With Gastroesophageal Cancer Opportunity
The analyst price target for BeOne Medicines has moved higher to reflect a fair value estimate of $292.03, with analysts pointing to stronger modeled revenue growth and profit margins, supported by recent Street research around Brukinsa performance, Ziihera phase III progress in HER2-positive GEA with Tevimbra, and continued confidence in the CLL and solid tumor pipeline. Analyst Commentary Recent Street research on BeOne Medicines has generally pointed to constructive views on the company’s core franchises, with several price targets adjusted higher alongside updates on Brukinsa, sonrotoclax, and the broader CLL and solid tumor pipeline.Uppdatering av berättelse • Dec 14
ONC: Priority Review And Trial Progress Will Drive Future Upside Momentum
Analysts have nudged their blended price target for BeOne Medicines up by about $3 to roughly $402, citing stronger confidence in the chronic lymphocytic leukemia and solid tumor pipelines, recent Ziihera and Tevimbra data, and repeated quarterly beats that support steadily improving margins despite a slightly higher discount rate. Analyst Commentary Bullish analysts point to a broad set of recent price target hikes in the high $380s to low $420s range as evidence that the market is re-rating BeOne Medicines higher on both execution and pipeline visibility.Uppdatering av berättelse • Nov 29
ONC: Priority Review And Trial Updates Will Drive Momentum Amid Sector Risks
BeOne Medicines’ analyst price target has edged up from $395 to $399, as analysts point to key clinical updates and solid quarterly performance as catalysts for incremental upside. Analyst Commentary Recent research notes from Street analysts highlight both strengths and risks for BeOne Medicines as the company navigates pivotal clinical developments and posts strong financial results.Uppdatering av berättelse • Nov 15
ONC: Pipeline Data And Conference Updates Will Shape Outlook Amid Sector Risks
Analysts have increased their fair value estimate for BeOne Medicines to $395.37 from $382.29, citing strong quarterly results as well as an improved outlook for key therapies and pipeline advancements. Analyst Commentary Bullish analysts emphasized several positive trends in BeOne Medicines' recent performance and outlook, resulting in a series of raised price targets and continued positive ratings.Analysartikel • Nov 14
We Think BeOne Medicines' (NASDAQ:ONC) Profit Is Only A Baseline For What They Can Achieve
Even though BeOne Medicines AG's ( NASDAQ:ONC ) recent earnings release was robust, the market didn't seem to notice...Uppdatering av berättelse • Nov 01
ONC: Pivotal Oncology Trial Data Will Drive Future Upside Momentum
BeOne Medicines' fair value price target has risen modestly by $1.20 to $382.29. Analysts cite increased confidence in peak sales for sonrotoclax and the company's broadly advancing oncology pipeline as key drivers for the upward adjustment.Uppdatering av berättelse • Oct 17
Oncology Trials And Global Expansion Will Unlock Future Markets
Analysts have raised their fair value price target for BeOne Medicines from $372.97 to $381.09. They cite accelerating revenue growth, an improved profit margin outlook, and positive pivotal trial catalysts as reasons for their more optimistic projections.Uppdatering av berättelse • Oct 03
Oncology Trials And Global Expansion Will Unlock Future Markets
Analysts have increased their fair value price target for BeOne Medicines by approximately $5 to $372.97. They cite robust Q2 sales growth, encouraging pipeline developments, and upward revisions to revenue forecasts as reasons for the adjustment.Uppdatering av berättelse • Sep 18
Oncology Trials And Global Expansion Will Unlock Future Markets
BeOne Medicines’ consensus price target was raised to $367.68, reflecting analyst optimism driven by robust sales growth, positive pipeline updates, profitability, and increased revenue guidance. Analyst Commentary Bullish analysts highlight BeOne Medicines’ broad oncology pipeline and upcoming pivotal data readouts—specifically BTK inhibitor data in mantle cell lymphoma and PD1 inhibitor/anti-HER2 combination results in gastroesophageal cancer—as key drivers for durable growth.Uppdatering av berättelse • Sep 03
Oncology Trials And Global Expansion Will Unlock Future Markets
The consensus analyst price target for BeOne Medicines was raised to $363.30, primarily driven by strong Brukinsa Q2 sales, improved forward revenue guidance, and ongoing pipeline progress. Analyst Commentary Bullish analysts cite robust Q2 sales growth, particularly from Brukinsa in the US and EU, as the main driver for upward price target revisions.Uppdatering av berättelse • Aug 08
Oncology Trials And Global Expansion Will Unlock Future Markets
With both revenue growth and net profit margin expectations remaining essentially unchanged, analysts have maintained BeOne Medicines’ fair value at a consensus price target of $357.18. What's in the News BeOne Medicines raised 2025 revenue guidance to $5.0–$5.3 billion, now expecting positive GAAP operating income.
Ny berättelse • Apr 24
US Facility And Phase III Trials Will Expand Markets
Expansion of manufacturing capabilities and global market presence aims to boost revenue and market share, particularly in B-cell malignancies.Aktieägarnas avkastning
| ONC | US Biotechs | US Marknad | |
|---|---|---|---|
| 7D | 3.3% | 6.3% | -1.2% |
| 1Y | 21.3% | 47.2% | 18.3% |
Avkastning vs industri: ONC presterade sämre än US Biotechs branschen som gav 47.2 % under det senaste året.
Avkastning vs Marknaden: ONC översteg US marknaden som gav 18.3 % under det senaste året.
Prisvolatilitet
| ONC volatility | |
|---|---|
| ONC Average Weekly Movement | 4.4% |
| Biotechs Industry Average Movement | 9.9% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.1% |
Stabil aktiekurs: ONC har inte haft någon betydande prisvolatilitet under de senaste 3 månaderna jämfört med marknaden för US.
Volatilitet över tid: ONC s veckovolatilitet ( 4% ) har varit stabil under det senaste året.
Om företaget
| Grundad | Anställda | VD OCH KONCERNCHEF | Webbplats |
|---|---|---|---|
| 2010 | 12,000 | John Oyler | beonemedicines.com |
BeOne Medicines AG är ett onkologibolag som bedriver forskning och utveckling av olika behandlingar för cancerpatienter i USA, Kina, Europa och internationellt. Bolagets produkter i kommersiell fas inkluderar BRUKINSA, en småmolekylär hämmare av Brutons tyrosinkinas (BTK) för behandling av olika blodcancerformer; TEVIMBRA, en immunoterapi med anti-PD-1-antikroppar för behandling av olika solida tumörer och blodcancerformer; SYLVANT för behandling av vuxna patienter med multicentrisk Castlemans sjukdom; BAITUOWEI för patienter med BC hos kvinnor före och under klimakteriet samt cancer; och PARTRUVIX för behandling av olika solida tumörer. Bolagets produkter i klinisk fas omfattar Sonrotoclax BGB-11417, en småmolekylär Bcl-2-hämmare; BGB-16673, en BTK-riktad chimär förening för nedbrytningsaktivering som är aktiv mot vildtyp och mutant BTK; BG-60366, en EGFR-riktad CDAC; BG-89894 (SYH2039), en MAT2A-hämmare; BGB-58067, en MTA-samverkande PRMT5-hämmare; BG-T187 och BG-C0902, en trispecifik anti-EGFRxMET-antikropp; BGB-26808, en HPK-1-hämmare; BGB-C354, en anti-B7H3 ADC; Zanidatamab, en bispecifik HER2-riktad antikropp; BG-C137, en anti-FGFR2b ADC; BGB-53038, en Pan-KRAS-hämmare; BGB-B2033, en bispecifik anti-GPC3x4-1BB-antikropp; BGB-B3227, en bispecifik antikropp mot MUC1xCD16A; BG-C477, en anti-CEAADC; BGB-43395, en CDK4-hämmare; BG-68501, en CDK2-hämmare; BG-C9074, en anti-B7H4 ADC; BGB-21447, en Bcl-2-hämmare; och BGB-45035, en IRAK4-riktad CDAC.
BeOne Medicines AG Sammanfattning av grunderna
| ONC grundläggande statistik | |
|---|---|
| Börsvärde | US$42.58b |
| Vinst(TTM) | US$655.71m |
| Intäkter(TTM) | US$6.13b |
64.9x
P/E-förhållande6.9x
P/S-förhållandeÄr ONC övervärderat?
Se Verkligt värde och värderingsanalysResultat & intäkter
| ONC resultaträkning (TTM) | |
|---|---|
| Intäkter | US$6.13b |
| Kostnad för intäkter | US$680.68m |
| Bruttovinst | US$5.45b |
| Övriga kostnader | US$4.79b |
| Intäkter | US$655.71m |
Senast redovisade vinst
Jun 30, 2026
Nästa vinstdatum
Aug 26, 2026
| Vinst per aktie (EPS) | 5.77 |
| Bruttomarginal | 88.89% |
| Nettovinstmarginal | 10.70% |
| Skuld/egenkapitalförhållande | 38.3% |
Hur har ONC utvecklats på lång sikt?
Se historisk utveckling och jämförelseFöretagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/08/24 16:07 |
| Aktiekurs vid dagens slut | 2026/08/21 00:00 |
| Intäkter | 2026/06/30 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som används för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och handledningar på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
BeOne Medicines AG bevakas av 69 analytiker. 34 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Tianli Wen | Aletheia Analyst Network Limited |
| Brian Skorney | Baird |
| Peter Lawson | Barclays |